Arda Therapeutics is pioneering a novel approach to treating chronic diseases by focusing on the selective elimination of pathogenic cells rather than merely modulating individual proteins or signaling pathways. This strategy is rooted in the understanding that complex chronic diseases often involve intricate regulatory networks, making it challenging to achieve significant therapeutic effects through traditional methods. By leveraging single-cell data, Arda identifies specific pathogenic cell populations and their unique surface markers, allowing for the design of targeted therapies that aim to deplete these harmful cells while sparing healthy tissue. This targeted cell depletion approach is expected to enhance therapeutic efficacy, streamline discovery timelines, and reduce the frequency of dosing compared to conventional treatments.

The company employs advanced technologies, including custom machine learning methods and single-cell sequencing, to create a comprehensive map of disease-specific cell states. This enables the identification of distinct subpopulations within historically monolithic cell types, facilitating the development of biologics that can selectively bind to and eliminate only the dysfunctional cells. Drawing inspiration from successful oncology strategies, Arda Therapeutics aims to apply immune-cell engaging biologics and other innovative modalities to target and eliminate non-malignant pathogenic cells. This approach not only holds promise for treating immunological and inflammatory diseases but also represents a significant shift in how chronic diseases may be addressed in the future.

United States

Arda is taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions.

Arda Therapeutics

Company Details